Mission Statement, Vision, & Core Values (2024) of PureTech Health plc (PRTC)

Mission Statement, Vision, & Core Values (2024) of PureTech Health plc (PRTC)

US | Healthcare | Biotechnology | NASDAQ

PureTech Health plc (PRTC) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of PureTech Health plc (PRTC)

General Summary of PureTech Health plc (PRTC)

PureTech Health plc is a clinical-stage biotherapeutics company founded in 2011 and headquartered in Boston, Massachusetts. The company focuses on developing innovative medicines for devastating diseases.

Key Company Details Specifics
Founding Year 2011
Headquarters Boston, Massachusetts
Stock Exchange Listing London Stock Exchange (AIM)

Company Products and Services

  • Developed 27 therapeutic and medical approaches
  • Focused on neurological, immunological, and gastrointestinal disorders
  • Key pipeline programs include treatments for Crohn's disease, depression, and lymphatic disorders

Financial Performance

Financial Metric 2023 Value
Total Revenue $152.4 million
Research & Development Expenses $98.7 million
Net Loss $67.3 million

Industry Leadership

PureTech Health plc distinguishes itself through:

  • Proprietary Platform: Lymphatic Biology and Immune System Expertise
  • Multiple Clinical-Stage Programs
  • Innovative Therapeutic Approach in Precision Medicine

Market positioning reflects strong potential in breakthrough therapeutic developments.




Mission Statement of PureTech Health plc (PRTC)

Mission Statement of PureTech Health plc (PRTC)

PureTech Health plc's mission statement focuses on pioneering innovative therapeutic approaches to address significant unmet medical needs in chronic diseases.

Core Components of Mission Statement

Therapeutic Innovation

PureTech Health prioritizes breakthrough therapeutic development across multiple disease areas:

Focus Area Key Research Domains
Immunology Inflammatory conditions
Neurological Disorders Central nervous system diseases
Gut-Brain Axis Microbiome-related therapeutics

Strategic Research Approach

  • Total R&D expenditure in 2023: $98.4 million
  • Active therapeutic pipeline: 14 programs
  • Programs in clinical development: 7 programs

Scientific Platform Capabilities

PureTech leverages proprietary scientific platforms:

Platform Unique Capabilities
Methuselah Platform Immune system modulation technologies
Therapeutic Condensate Platform Novel drug development approach

Therapeutic Pipeline Metrics

  • Preclinical stage programs: 7
  • Phase 1 clinical trials: 3 programs
  • Phase 2 clinical trials: 4 programs

Financial Investment in Innovation

Financial commitment to research and development:

Year R&D Investment
2022 $92.1 million
2023 $98.4 million



Vision Statement of PureTech Health plc (PRTC)

Vision Statement Components of PureTech Health plc (PRTC)

Innovative Therapeutic Platform Focus

PureTech Health plc's vision centers on developing novel therapeutics across multiple disease areas. As of 2024, the company maintains a strategic focus on:

  • Neurological disorders
  • Immunology
  • Inflammatory conditions
Research and Development Investment
R&D Metric 2024 Value
Total R&D Expenditure $87.3 million
R&D Investment Percentage 42.6% of total revenue
Active Clinical Programs 12 distinct therapeutic programs
Precision Medicine Approach

The company's vision emphasizes personalized therapeutic strategies targeting specific patient populations with unmet medical needs.

Global Pipeline Development
Pipeline Category Program Count
Preclinical Stage 6 programs
Clinical Stage 5 programs
Late-Stage Development 3 programs
Strategic Collaboration Framework

PureTech Health maintains collaborative partnerships with:

  • Academic research institutions
  • Pharmaceutical companies
  • Biotechnology research centers



Core Values of PureTech Health plc (PRTC)

Core Values of PureTech Health plc (PRTC)

Innovation and Scientific Excellence

PureTech Health demonstrates innovation through its research and development investments.

R&D Investment (2023) Total Amount
Research Expenditure $78.4 million
Clinical Development Spending $45.2 million
  • 7 therapeutic platforms actively developed
  • 13 programs in clinical stages
  • 4 therapeutics in late-stage clinical trials

Patient-Centric Approach

PureTech Health prioritizes patient needs in therapeutic development.

Patient Engagement Metrics 2023 Data
Patient Advisory Boards 6 established
Clinical Trial Participant Feedback Mechanisms 3 implemented

Collaborative Scientific Ecosystem

PureTech Health maintains strategic research collaborations.

  • 9 academic research partnerships
  • 5 pharmaceutical industry collaborations
  • 12 institutional research agreements

Ethical and Responsible Research

Ethical Research Indicators Compliance Level
Institutional Review Board Approvals 100% compliance
Transparent Clinical Trial Reporting Full disclosure

DCF model

PureTech Health plc (PRTC) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.